Catalyst Wire Dossier Catalyst Wire Dossier

Maviret

glecaprevir/pibrentasvir · AbbVie
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Maviret, covering 2024-07-19 to 2026-07-15. Get the full timeline:

Most recent: EMA Authorised: Maviret (glecaprevir;pibrentasvir) — AbbVie Deutschland GmbH & Co. KG

See pricing